385 related articles for article (PubMed ID: 9417143)
1. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.
Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; uberall M; Laussucq S; Eckhardt T; Meyer M; Engelhardt R; Christenson P
Pediatrics; 1998 Jan; 101(1 Pt 1):1-11. PubMed ID: 9417143
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
Heininger U; Cherry JD; Stehr K; Schmitt-Grohé S; Uberall M; Laussucq S; Eckhardt T; Meyer M; Gornbein J
Pediatrics; 1998 Sep; 102(3 Pt 1):546-53. PubMed ID: 9738175
[TBL] [Abstract][Full Text] [Related]
3. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
[TBL] [Abstract][Full Text] [Related]
4. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
Heininger U; Stehr K; Christenson P; Cherry JD
Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
[TBL] [Abstract][Full Text] [Related]
5. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
6. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
[TBL] [Abstract][Full Text] [Related]
7. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
8. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
Stehr K; Cherry JD
Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
[No Abstract] [Full Text] [Related]
9. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine.
Lugauer S; Heininger U; Cherry JD; Stehr K
Eur J Pediatr; 2002 Mar; 161(3):142-6. PubMed ID: 11998910
[TBL] [Abstract][Full Text] [Related]
10. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of endotoxin concentrations in vaccines.
Geier DA; Geier MR
Ann Pharmacother; 2002 May; 36(5):776-80. PubMed ID: 11978151
[TBL] [Abstract][Full Text] [Related]
12. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial.
Cherry JD; Heininger U; Stehr K; Christenson P
Pediatrics; 1998 Oct; 102(4 Pt 1):909-12. PubMed ID: 9755264
[TBL] [Abstract][Full Text] [Related]
13. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
Matheson AJ; Goa KL
Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
[TBL] [Abstract][Full Text] [Related]
14. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany.
Heininger U; Cherry JD; Christenson PD; Eckhardt T; Göering U; Jakob P; Kasper W; Schweingel D; Laussucq S; Hackell JG
Vaccine; 1994 Jan; 12(1):81-6. PubMed ID: 8303945
[TBL] [Abstract][Full Text] [Related]
16. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
17. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.
Tozzi AE; Anemona A; Stefanelli P; Salmaso S; Ciofi degli Atti ML; Mastrantonio P; Giammanco A;
Pediatrics; 2001 Feb; 107(2):E25. PubMed ID: 11158499
[TBL] [Abstract][Full Text] [Related]
18. A placebo-controlled trial of a pertussis-toxoid vaccine.
Trollfors B; Taranger J; Lagergård T; Lind L; Sundh V; Zackrisson G; Lowe CU; Blackwelder W; Robbins JB
N Engl J Med; 1995 Oct; 333(16):1045-50. PubMed ID: 7675047
[TBL] [Abstract][Full Text] [Related]
19. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.
Olin P; Rasmussen F; Gustafsson L; Hallander HO; Heijbel H
Lancet; 1997 Nov; 350(9091):1569-77. PubMed ID: 9393335
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
